Milestone Pharmaceuticals study finds PSVT curbs daily activities, drives anxiety between episodes
MIST•Study highlights quality-of-life burden between PSVT episodes
Milestone Pharmaceuticals flagged new longitudinal study findings on how PSVT affects daily life between episodes.
- Results will be presented Aug. 30, 2026 at the European Society of Cardiology Congress 2026 in a moderated ePoster session.
- Patient-reported data showed sustained quality-of-life burden between episodes, with frequent activity disruption, avoidance behaviors, sleep or work dissatisfaction.
- Persistent anxiety between episodes emerged as a recurring issue, reinforcing that impact extends beyond acute events.
- Chronic medication side effects were commonly viewed as burdensome, supporting the case for alternative at-home episode-termination options.
